Zweig-DiMenna Associates’s Gilead Sciences GILD Stock Holding History

Zweig-DiMenna Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,700	Closed	-$462K	–	155
2017 Q3	$462K	Buy	+5,700	New	+$436K	0.04%	123
2016 Q4	–	Sell	-2,700	Closed	-$214K	–	226
2016 Q3	$214K	Hold	2,700	–	–	0.02%	165
2016 Q2	$225K	Buy	+2,700	New	+$240K	0.02%	121
2016 Q1	–	Sell	-30,000	Closed	-$3.04M	–	221
2015 Q4	$3.04M	Sell	30,000 -87,400	-74%	-$9.09M	0.15%	121
2015 Q3	$11.5M	Buy	+117,400	New	+$13M	0.5%	60
2015 Q2	–	Sell	-2,500	Closed	-$245K	–	274
2015 Q1	$245K	Sell	2,500 -200	-7%	-$20.3K	0.01%	247
2014 Q4	$255K	Sell	2,700 -101,395	-97%	-$10.5M	0.01%	203
2014 Q3	$11.1M	Sell	104,095 -100,886	-49%	-$9.88M	0.48%	71
2014 Q2	$17M	Buy	204,981 +42,670	+26%	+$3.32M	0.78%	48
2014 Q1	$11.5M	Sell	162,311 -386,046	-70%	-$30.3M	0.68%	55
2013 Q4	$41.2M	Buy	548,357 +193,178	+54%	+$13.5M	1.51%	13
2013 Q3	$22.3M	Buy	355,179 +7,320	+2%	+$437K	0.91%	39
2013 Q2	$17.8M	Buy	+347,859	New	+$18.1M	0.72%	58

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Zweig-DiMenna Associates's GILD Position: Q4 2017 in Review

Zweig-DiMenna Associates sold out of Gilead Sciences (GILD) in Q4 2017, closing a stake of 5,700 shares — an estimated $462K sold.

Zweig-DiMenna Associates first reported a position in GILD in Q2 2013 and held it in 13 quarters. The position peaked at $41.2M in Q4 2013. 1,576 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

Zweig-DiMenna Associates reported no remaining Gilead Sciences position as of Q4 2017 after selling out during the quarter.
Zweig-DiMenna Associates sold 5,700 Gilead Sciences shares in Q4 2017, an estimated $462K.
Zweig-DiMenna Associates first reported a position in Gilead Sciences in Q2 2013 and held it in 13 quarters.
Zweig-DiMenna Associates's Gilead Sciences position peaked at $41.2M in Q4 2013.
1,576 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on Zweig-DiMenna Associates's 13F filing for Q4 2017, filed 12 Feb 2018.